論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
掲載誌名	正式名：International journal of clinical oncology 略　 称：Int J Clin Oncol ISSNコード：14377772/13419625
掲載区分	国外
巻・号・頁	30(10),pp.1963-1971
著者・共著者	Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Koichi Takayama
発行年月	2025/10
概要	BACKGROUND:In Japan, chemoimmunotherapy was approved as treatment for advanced or recurrent non-small-cell lung cancer (NSCLC), including for patients with epidermal growth factor receptor (EGFR) mutations, in December 2018. However, the impact of its approval on real-world clinical outcomes among patients with EGFR-mutant NSCLC remains unclear. The aim of our study was to assess that impact.METHODS:We retrospectively assessed consecutive patients with advanced or recurrent EGFR-mutant NSCLC who received platinum-based cancer therapy after EGFR-tyrosine kinase inhibitors (TKIs) at 20 institutions in Japan from January 2017 to July 2022.RESULTS:We evaluated 120 (27.2%) patients before the chemoimmunotherapy approval and 321 (72.8%) after. Overall, no significant differences in progression-free survival (PFS) or overall survival (OS) were observed between the pre- and post-approval groups (p = 0.72 and p = 0.89, respectively). In the subgroup with programmed cell death-ligand 1 (PD-L1) expression ≥ 50%, the post-approval group had a significantly longer PFS (p = 0.007) and OS (p = 0.048) than the pre-approval group. In contrast, in the PD-L1 < 50% cohort, no significant differences in the PFS (p = 0.54) or OS (p = 0.75) were noted between the groups.CONCLUSIONS:The approval of chemoimmunotherapy did not affect treatment outcomes among patients with EGFR-mutant NSCLC who received platinum-based therapy after EGFR-TKIs. However, patients with high levels of PD-L1 expression had improved outcomes post-approval, suggesting potential benefits in this subgroup.
DOI	10.1007/s10147-025-02837-8
PMID	40691734